• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA delays action on Immunomedics agent

Article

Monoclonal antibody developer Immunomedics suffered a blow fromthe Food and Drug Administration last week. The agency's oncologicdrugs advisory committee deferred a decision on the company'sCEA-Scan colorectal cancer imaging agent and recommended thatit

Monoclonal antibody developer Immunomedics suffered a blow fromthe Food and Drug Administration last week. The agency's oncologicdrugs advisory committee deferred a decision on the company'sCEA-Scan colorectal cancer imaging agent and recommended thatit be reviewed by another FDA committee. News of the committee'sdecision caused the Morris Plains, NJ, company's stock to drop26% to $5.75 a share on Oct. 18.

The FDA last year issued Immunomedics a non-approvable letterfor CEA-Scan (SCAN 9/27/95). Immunomedics said it will continueto work with the FDA to receive approval for the agent.

Related Videos
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Related Content
© 2024 MJH Life Sciences

All rights reserved.